Nectar RHS Komplementar ApS: Financial statements 2022
CVR: 41934530
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Nectar RHS Komplementar ApS (CVR 41934530) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -12,500 and a net result of DKK 9,585 compared with DKK 15,600 the year before. Equity in the 2022 report amounted to DKK 65,185. The solvency ratio was 84.1%.
- Gross Profit
- DKK -12,500
- Profit/Loss
- DKK 9,585
- Equity
- DKK 65,185
- Total Assets
- DKK 77,500
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -13 t. | 10 t. | 65 t. | 0 |
| 2021 | - | -5 t. | 16 t. | 56 t. | 0 |
Keep an eye on Nectar RHS Komplementar ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Nectar RHS Komplementar ApS has published its annual report for 2021. Gross profit came to DKK -5,000, and the net result was DKK 15,600.
About Nectar RHS Komplementar ApS
Nectar RHS Komplementar ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Bjørk Krogshave. The company is owned by PharmaService I/S and Nectar Invest A/S. In 2025, the company reported a gross profit of DKK -5,000 and a net result of DKK 38,849 compared with DKK 58,075 the year before. Equity in the 2025 report amounted to DKK 177,416.